, Tracking Stock Market Picks
Enter Symbol:
Charles River Laboratories International, Inc. (CRL) [hlAlert]

up 114.53 %

Charles River Laboratories International, Inc. (CRL) rated Outperform with price target $37 by Robert W. Baird

Posted on: Wednesday,  May 12, 2010  4:25 PM ET by Robert W. Baird

Robert W. Baird rated Outperform Charles River Laboratories International, Inc. (NYSE: CRL) on 05/12/2010, when the stock price was $32.68.
Since then, Charles River Laboratories International, Inc. has gained 114.53% as of 01/22/2016's recent price of $70.11.
If you would have followed this Robert W. Baird's recommendation on CRL, you would have gained 114.53% of your investment in 2081 days.

Charles River Laboratories International, Inc. (Charles River) is a global provider of solutions that advance the drug discovery and development process, including research models and associated services, and outsourced preclinical services. The Company operates in two segments: Research Models and Services (RMS) and Preclinical Services (PCS). The Company provides the animal research models required in research and development of drugs, devices and therapies. Charles River?s customer base includes global pharmaceutical companies, a range of biotechnology companies, as well as government agencies, hospitals and academic institutions worldwide. The Company operates approximately 70 facilities in 17 countries worldwide. During the fiscal year ended December 27, 2008 (fiscal 2008), the Company acquired NewLab BioQuality AG and MIR Preclinical Services.

Deep, comprehensive coverage is essential to your success. And with nearly 100 research professionals covering over 500 U.S. companies, our reputation for trusted, award-winning, in-depth analysis with a strong commitment to objective, fundamental research speaks for itself.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/12/2010 4:25 PM Buy
32.68 37.00
as of 12/31/2010
1 Week up  4.25 %
1 Month up  13.99 %
3 Months up  12.27 %
1 YTD up  13.89 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy